血液透析人群中三剂mRNA新冠疫苗在奥密克戎期间的有效性
加拿大安大略省回顾性队列研究纳入8457例维持性血液透析患者,比较接种两剂与三剂mRNA新冠疫苗在奥密克戎流行期间的效果。三剂疫苗与较低的SARS-CoV-2感染风险(aHR 0.58,95%CI 0.50-0.67)和重症结局风险(aHR 0.40,95%CI 0.28-0.56)相关。既往感染独立于疫苗状态与较低的再感染风险相关(aHR 0.44,95%CI 0.27-0.73)。
要点
- 在血液透析人群中,三剂mRNA疫苗较两剂与较低的SARS-CoV-2感染风险相关(aHR 0.58,95%CI 0.50-0.67)。
- 三剂疫苗较两剂与较低的SARS-CoV-2相关重症结局风险相关(aHR 0.40,95%CI 0.28-0.56)。
- 既往感染独立于疫苗状态与较低的再感染风险相关(aHR 0.44,95%CI 0.27-0.73)。
核心结论
- 在奥密克戎流行期间,三剂mRNA新冠疫苗接种较两剂与较低的SARS-CoV-2感染发生率和SARS-CoV-2相关重症结局发生率相关。
研究设计与样本
- 加拿大安大略省回顾性队列研究,纳入2021年12月1日至2022年2月28日期间接受维持性血液透析且已接种两剂或三剂mRNA新冠疫苗的人群。
- 共纳入8457例接受中心血液透析的个体。
- 研究开始时2334例(28%)已接种三剂,至研究期末增至7468例(88%)。
- 新冠疫苗接种、SARS-CoV-2感染及相关住院和死亡信息来自省级数据库。
- 主要结局为首次RT-PCR确诊的SARS-CoV-2感染,次要结局为SARS-CoV-2相关重症结局(住院或死亡)。
主要发现
- 三剂较两剂mRNA疫苗后SARS-CoV-2感染的调整风险比(aHR)为0.58(95%CI 0.50-0.67)。
- 三剂较两剂mRNA疫苗后SARS-CoV-2相关重症结局(住院或死亡)的aHR为0.40(95%CI 0.28-0.56)。
- 既往感染独立于疫苗状态与较低的再感染风险相关,aHR为0.44(95%CI 0.27-0.73)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) vaccine effectiveness studies in the hemodialysis population have demonstrated that two doses of mRNA COVID-19 vaccines are effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe complications when Alpha and Delta were predominant variants of concern. Vaccine effectiveness after a third dose versus two doses for preventing SARS-CoV-2 infection and severe COVID-19 in the hemodialysis population against Omicron is not known. METHODS: We conducted a retrospective cohort study in Ontario, Canada, between December 1, 2021, and February 28, 2022, in the maintenance hemodialysis population who had received two versus three doses of mRNA COVID-19 vaccines. COVID-19 vaccination, SARS-CoV-2 infection, and related hospitalization and death were determined from provincial databases. The primary outcome was the first RT-PCR confirmed SARS-CoV-2 infection, and the secondary outcome was a SARS-CoV-2-related severe outcome, defined as either hospitalization or death. RESULTS: A total of 8457 individuals receiving in-center hemodialysis were included. At study initiation, 2334 (28%) individuals received three doses, which increased to 7468 (88%) individuals by the end of the study period. The adjusted hazard ratios (aHR) for SARS-CoV-2 infection (aHR, 0.58; 95% confidence interval [CI], 0.50 to 0.67) and severe outcomes (hospitalization or death) (aHR, 0.40; 95% CI, 0.28 to 0.56) were lower after three versus two doses of mRNA vaccine. Prior infection, independent of vaccine status, was associated with a lower risk of reinfection, with an aHR of 0.44 (95% CI, 0.27 to 0.73). CONCLUSIONS: Three-dose mRNA COVID-19 vaccination was associated with lower incidence of SARS-CoV-2 infection and severe SARS-CoV-2-related outcomes during the Omicron period compared with two doses.
引用
- Wing S, Thomas D, Balamchi S, et al. Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period. Clin J Am Soc Nephrol. 2023. PMID: 36723290. doi:10.2215/CJN.0000000000000108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。